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INTRODUCTION   
Breast cancer has been known since ancient times to mankind. Physicians from 
early times recorded the visible transformation and progression of lumps in breast to 
tumors. Among  all  cancers, breast cancer has been subjected to  more  research,  since  
the  treatment  involves  surgery  which  leaves emotional  and  physical  scars  in  its  
victims. 
Breast carcinoma is the most common cancer in women. In women it  is  the  leading  
cause  of  death ,  with  more  than a  million  cases annually reported  worldwide (1).  
Among the public  health  issues, Breast  cancer  has an important representation  with  
a  high  occurrence  worldwide, also with  an    increasing  tendency  (2). 
In 3500 B.C. ancient Egyptians were the first to record the breast tumor in their literature 
(3). Fairly accurate description was given by both Edwin Smith and George Ebers 
papyri as “Bulging tumors of the breast that has no cure”. In 460 B.C., the father of 
western medicine Hippocrates described breast carcinoma as a humoral disease. 
The  incidence  of  cancer  has  been  on  rise  worldwide.  Breast  cancer  incidence  
accounts  for  16%  of  all  breast  cancers,  as  per  the  WHO  cancer  control  and  
prevention  program.  It  is  calculated  that  519  women  died  owing  to  breast  
malignancy  in  2004  (4).  Inspite  of  the  fact,  breast  cancer  is  thought  to  be  a  
disease  of  the  developed  world,  majority  of      breast  cancer  mortality  (69%),  is  
in  developing  countries  (4).  Hence  breast  cancer  has  emerged  to  be  one  of  the  
leading  cancer  killers  amongst  women  worldwide. 
Over  the  last  few  decades  there  have  been  better  advances  in  breast  cancer.  
Early  detection    and  skillful    treatment  has  led  to  a  significant  decline    in  breast  
cancer  deaths.    It  has  also  made  improved  outcome  for  women  living  with  the  
disease.  Breast  cancer  is  no  longer  seen  as  single  disease  but  rather  a  multifaceted  
disease  consisting  of  diverse  biological  subtypes  with  distinct  natural  history.  
Breast  cancer  presents  as  a  varied  spectrum  of  clinical,  pathological  and  molecular  
features  with  diverse  prognostic  and  therapeutic  implications. 
Estrogen  is  the  steroid  hormone,  responsible  for  development  and  maturation  of  
primary  and  secondary  sexual  characteristics  in  females  (5).  Estrogen  has  an  
important  role      in  pathogenesis  and  development  of  breast  cancer  (6). 
Estrogen  receptor  is  an  intracellular  protein  molecule.    It  is the targets  for  estrogen  
action.  Estrogen  receptor  normally  resides  in  cell  nucleus,  along  with  DNA  
molecules.  Estrogen  receptor  alpha  gene  polymorphism  leads  to  alteration  in  
estrogen  receptor  function  in  breast  cancer  (7). 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
• To  study  the prognostic impact  of the presence of stromal mast cells   in  breast  
carcinoma   
• To  study  relationship  with  certain  prognostic  factors  like, 
 1.  Age, 
 2.  Nottingham’s grade 
 3.  ER, PR, HER 2 neu 
• To study the role of stromal mast cells in breast carcinoma. 
 
 
 
 
 
 
 
 
REVIEW    OF   LITERATURE 
Brief introduction about the development and anatomy of breast will lay a better 
pavement for understanding the process of breast cancer. 
Development of human breast tissue: 
Human breast is a specialized apocrine gland. Development of breast starts from 
fifth week of gestation. On the ventral surface of the fetus thickening of the ectoderm 
appears. It extends from the axilla to the groin to form “milk line. As the fetus develops 
the milk line regresses except for the pectoral region to form the primary mammary bud. 
During tenth week primary mammary bud penetrate the underlying mesenchyme, begin 
to branch into 15-25 secondary buds. Secondary buds develops into lobules by 12 week. 
A small Lumina develops in buds to form lactiferous ducts during 20 week. Meanwhile 
the mesoderm give rise to supporting structures like fibrous tissue, coopers ligaments 
and fat.  
During the late fetal period, the nipple and areola arise from the mammary pit. 
Mammary pit is nothing but an infolding of epidermis, and its surrounding connective 
tissue and mesenchyme. At birth, 15-25 lactiferous ducts open into mammary pit. 
Proliferation of underlying mesoderm converts the pit into an everted nipple. No further 
development occurs until puberty.(8)  
 
 
 
Anatomy of human breast: 
Breast is made up of parenchymal  tissues  composed  of    branching  ductal  
system  which are radiating  from  the  nipple.   15-20 mammary lobules are usually 
present in breast parenchyma.  Lactiferous duct drains the lobules to the nipple.  Lobules 
are separated from each another by interlobar connective tissue.   Before  entering  the  
nipple,    15-20  main  ducts ,each expands  to form  a  dilated  segment  known as  the  
lactiferous  sinus.  Every  lobe  consists  of  30-80  lobules,  which  are the  milk-forming  
elements  of  the  breast. Each lobules   composed of 20-40   terminal units or acini. 
Lobules are surrounded by   intralobar   connective tissue.  These intralobar connective 
tissue are hormonally sensitive. The  proportion  of  fibrous,  fat  and  parenchymal  
tissue  vary    between  individuals  and also with  weight, menopausal status,  genetic 
factors and the  number  of  live  births   (9). 
Role of hormones in breast: 
    Only rudimentary ductal system and nipples are present in female before puberty. At 
puberty, breast enlarge rapidly as a result of the development of fat and connective 
tissue. Ducts enlarges under the stimulation of estrogen and progesterone from the 
ovary. 
 
 
 
 
Cellular changes in breast during puberty: 
During pubertal development both parenchymal and stromal changes occurs at 
the cellular level (10). Stromal development occurs first with the proliferation of fibrous 
and fatty tissue. Later the ductal changes occur. Ductal changes includes ductal 
elongation and dichotomous branching. Both ductal and stromal changes are under the 
influence of estrogen (10).  Ductal elongation occurs under the influence of estrogen 
and progesterone is responsible for ductal branching(11). 
During puberty, the epithelium turns into a bilayer branching ductal structure. Duct 
composed of inner luminal epithelial cells and outer basal myoepithelial cells. Epithelial 
cells lining the alveoli are called alveolar luminal cells . These alveolar epithelial cells 
secrete milk during lactation. More and more alveoli are laid down during each 
menstrual  cycle.(12)   
 
 
 
 
 
 
 
 
CARCINOMA   OF THE BREAST 
  Due  to  uncontrolled  growth  of  the  epithelial  cells  at  the  junction  of  the  
terminal  duct-lobular  unit, carcinoma arises.  It takes about 5-10 years for a single 
malignant cell to form a mass of about 5-10 mm diameter.(12). 
EPIDEMIOLOGY 
Both in the developed and in the developing countries the most common cancer 
in women is the breast cancer.   In 2011 5,08,000 women died due to breast cancer 
worldwide.  (13). Though breast carcinoma is considered to be a disease of developing 
countries, around 50 % cancer cases and 58% death due to breast cancer occur in less 
developing nation.(13)Incidence of Cervical  cancer    is  higher in developing nations  
than  breast  cancer  ,  and vice versa  in  developed  countries. 
Incidence of breast cancer vary greatly worldwide. In Eastern Africa it is 19.3 per 
100,000 women and 89.7 per 100000 women in Western Europe. Thus the lowest 
incidence rates are seen in African countries.(13) 
 Breast  cancer  is  the  second  most  common  cancer  in  women  in India after  
cervical  cancer.  However  in  Indian cities  ,  breast  cancer  has  become  the  most  
common  cancer  rather than  cervical  cancer  (14).   
Incidence of breast cancer in India is 26% for the   year 2016. Mortality is 12.7 per 
100,000 women. Incidence was found to be high in Delhi with 41 per 100,000 women, 
followed by Chennai with 37.9 per 100,000 women. Mortality –to –incidence ratio is 
66 in rural areas and 8 in urban registries. (15). 
The variation in   incidence is due to multiple factors like    racial/ethnic background, 
geographical variation, lifestyle, socio-economic status,   and environmental 
factors, reproductive, hormonal, nutritional and genetic factors.  (16) 
 The  incidence  of  breast  cancer  has  been on  increase   due  to  the detection  of  
more  number  of  cases  with the   introduction  of  screening by mammography in  
early  1980’s  (17). 
The   aim  of  screening  is  to detect   in  situ  carcinomas ,  and predominantly  ER  
positive  invasive  carcinomas. Since 1980 there has been a constant increase in the 
diagnosis of   DCIS. This is due to the introduction of screening mammography. DCIS 
is almost   exclusively detected by mammography. Because of the screening 
mammography, the number of advanced stage breast carcinoma, huge node positive 
breast carcinoma has decreased and the number of   early stage   cancers with node 
negativity has increased   (17). 
During   the 1980’s death rate due to breast cancer remains constant though there was 
an increase in its incidence.  Since   1994, the    mortality rate   shows slow declination 
from 30% to 20%.  This  decrease  is  mainly due to  the early detection  of  breast 
cancers  at  a  curable  stage  by screening    and also by  improved  effective  
treatment  modalities  (18) 
In the last decade   the incidence of   invasive   breast cancer with Estrogen receptor 
positivity    has raised.  The   reason is   multi   factorial.     
  
RISK FACTORS 
Among the multi factorial disease, breast cancer is the most common cancer with 
high mortality rate. The risk factors are broadly classified into modifiable risk factors 
and non- modifiable risk factors. Some of the modifiable risk factors includes diet, 
obesity, exercise and breast feeding. Some  of  the non-modifiable risk   factors  are  
genetic  changes   in  tumor  suppressor  genes, oncogenes, growth  factor  imbalances,  
telomerase  activity and enzyme production.  The  genetic  changes  and non-genetic  
factors interact with each other  such  as    nutrition, environmental changes  and  other  
lifestyle  risk  factors  leading  to  carcinoma.  Breast cancer can be prevented by 
identifying the modifiable risk factors and avoiding them. 
I. Reproductive risk factors: 
A.  Early menarche and late menopause: 
 Menarche at a younger age increases risk of breast  cancer.  Females attaining menarche 
before 11 years of age have 20 % more risk for breast cancer when compared with 
females having menarche greater than 14 years of age.(19). Thus the frequency of breast 
cancer decrease by 10 – 20 % for every one year delay in menarche.  Both  onset  of  
menarche  and  regular  menstrual cycles  influence  the  breast  cancer.  Early menarche 
leads to prolonged exposure of  breast to estrogen which favors the process of 
carcinogenesis  (20) 
Women’s whose menopause falling between 45 to 54 years of age have comparatively 
reduced risk of breast cancer when compared with   women whose     menopause falling 
above 55 years of age. Relative risk is 1 for women with menopause between 45 to 54 
years when compared to relative risk of 1.48 for women with menopause above 55 
years.  Long menstrual history and ovarian dysfunction attributes to the cause of 
increase in breast cancer for women with late menopause   (21).   Women  with  
surgically  induced  menopause tends to  have  reduced  risks  when  compared  to  
women  with naturally occurring menopause .  
B.  Parity   
Nulliparous women have greater risk for breast cancer when compared to 
parous women. Nulliparous above 40 years are more prone for breast carcinoma. 
Among the parous, first full term pregnancy at latter age are associated with modest 
increase of breast carcinoma (22).  Risk also increases initially after the first 
pregnancy, after 10-15 years it then decreases. It can be explained by pregnancy 
induced proliferative changes  in  breast.  Regardless of the age at first birth, multiple 
full-term pregnancies decrease the risk of breast cancers. Early age at   first   
pregnancy   decreases   risk   of   breast   cancer.(22). 
 
C.  Age at first   live birth 
   First pregnancy at an early age   makes the maturation   of terminal ductal 
lobular unit  of  breast.  Thus it   reduces the risk of breast cancer.  Women who gave 
her first live birth before her 18 years have 60 % decreased risk of breast cancer when 
compared with women whose first live birth is above 35 years. (23).   
  
 D.  Breast feeding 
 Breast feeding can reduces the   risk   of breast cancer. If a women breast feeds 
for whole one year then  there  is   12%  decrease  in  relative  risk  for breast  cancer    
(24).  This reduction percentage is as high as   50% in multi parous females. 
The reason beyond this is due to fewer menstrual cycles for women who breast feed, 
resulting in lower estrogen levels. 
E.  Hormones   
 Breast development and functions all depends upon the various steroidal 
hormones synthesized in our body.   In  the  following  sections,  the  relation  between  
the  hormonal  levels  and  the risk for breast  cancer    will  be  discussed. 
F.  Estrogens and Androgens 
Estrogen plays a major role in breast development. It is mainly responsible for 
proliferation of the cells in breast.  The site of estrogen production varies between the 
premenopausal and postmenopausal women. In premenopausal women ovary is the site 
of estrogen production. After menopause ovary stops its synthetic function and adrenals 
become the source of estrogen. Adrenal androgen is aromatized to give rise to estrogen.  
Among multiple forms of Estrogen, Estradiol and Estrone sulfate are  responsible for 
breast  cancer  development. From  puberty  till  menopause the  17β  estradiol  is  the  
most    active  form  of  Estrogen  .  Estradiol can be seen in two states. One as a free 
hormone, circulating in  the  blood. Another form is the bound form. It is  bound  to the 
sex  hormone  –binding  globulin  (SHBG)  and  albumin.  Free  estradiol  or  estrogen,   
bound  to  albumin  are  functionally  more  active  than Estrone sulfate forms. Estrone 
sulfate constitutes the major circulating estrogen. In postmenopausal women they  are  
the  major  resource  of  Estrogen  from  adipose  tissue.   
Either  in  the  ovaries  or  in the adipose  tissues  , Androgens  like testosterone  and  
androstenedione  can  be  aromatized  into  Estrogens.   
Risk of  breast  cancer    is  directly  proportional  to  the  serum  concentrations  of  
sex  hormones  including   Estradiol, Testosterone Androstenedione  (25). 
Regardless of the menopausal status, Asian women seems to have low levels of Serum 
Estradiol when compared with western population.  These  differences  may  be  due  to 
late onset of menarche which reduces the  number  of  ovulatory  cycles,   multi  parity,   
breast  feeding,  and for longer duration   and  early    menopause. 
In  postmenopausal  women,  weight  is  directly  proportional  to  plasma  levels  of  
estrone  and  estradiol,  as  well  as  unbound  estradiol  to  SHBG.  Hence  
postmenopausal  obese  women  have  greater  risk  of  breast  cancer  development  
than  in  non-obese  women. 
G.  Hormone replacement therapy 
Initially hormone replacement therapy was considered to be a risk factor for breast 
carcinoma. It was thought that women who were taking hormone replacement therapy 
continuously for more than five years developed breast cancer in their future. But now 
it was found that there was no significant difference in the incidence of breast cancer 
among women who took hormone replacement therapy and who did not. Thus hormone 
replacement therapy only promotes the growth of cancer and has no direct genotoxic 
effect.  
Risk of breast cancer increases by 2.3 % every year for women who are currently on 
hormonal replacement therapy or who stopped using it within four years. Relative risk 
of breast cancer for women who had taken hormone replacement therapy for greater 
than 5 years is 1.35.(26) 
II.Anthropometric risk factors 
 Body mass index and breast cancer correlation, changes with the menopausal status. 
Increased weight and BMI decrease the breast cancer risk among pre-menopausal 
women. But it increases the risk among post-menopausal women.  
There are several hypothesis exist to explain the reason for reduction of breast cancer 
among the obese pre-menopausal women. Obese female used to have anovulatory cycle 
which leads to reduced progesterone secretion in the luteal phase. Fat stores have leptin 
which increases with obesity. Leptin will inhibit estrogen production from the ovary, 
thereby decreases the risk of breast cancer in pre-menopausal women.   
In the post-menopausal women the principle source of estrogen is the adipose tissue. 
Androstenedione in the adipose tissue is aromatized to estrone in post-menopausal 
women. When the adipose tissue increases the circulating levels of sex hormone binding 
globulin decreases thereby increasing the free estradiol levels. Obesity increases the 
concentration of circulating cytokines which stimulate the enzymes involved in 
estrogen synthesis.(27) 
III. Family history / Genetic factors 
Well established risk factor for breast cancer is the family history of breast 
cancer. Among the family history only few history are important. Women with relatives 
who developed their breast cancer in  post-menopausal stage have no significant 
increase in breast cancer. They are not genetically predisposed. But women whose have 
first degree relations with breast cancer have substantial increase risk for breast cancer. 
They have 1.5-2 times increased risk. If more than one first degree relative is affected 
by breast cancer then the risk increase to 6 times. Breast cancer develop at an early age 
in the affected women when compared to their affected first degree relations. BRCA 1 
and BRCA 2 gene mutations are also commonly seen with an increased inheritance in 
these population.  
Lynch differentiates hereditary breast cancer from familial breast cancer.  Familial  
breast  cancer  is  defined  as  “Family  having  more  than  two  first  degree  relatives  
with  breast  cancer  in  the  absence  of  hereditary  breast  cancer”.  Hereditary  breast  
cancer  is  defined  as  “Pattern  within  a  particular  family      having  Mendelian  
segregation  of  breast  cancer”. Familial breast cancer are probably  events  that  may  
happen,  by  the  laws  of  probability  to  cluster  in  a  family, but hereditary cancers  
are the  results  of  inheritance  of  abnormal  DNA  (28) 
5 % of breast cancer cases are associated with genetic factors. But the association with 
genetic factors increases to 25% among breast cancer women who are less than 30 years 
of age. Multiple genes are implicated in breast cancer. BRCA 1 and BRCA 2 are the 
genes involved in majority of inherited breast carcinomas. BRCA 1 gene is located on 
chromosome 17 and BRCA 2 gene is located on chromosome 13. Among the breast 
cancers only 2-5%  are  hereditary. Both BRCA 1 and BRCA 2 are tumor suppressor 
gene with numerous cell functions. Their main functions are DNA repair, gene 
transcription and regulation of cell cycle check point.    
Other than BRCA genes, several other genes are involved in breast cancer. They are 
Tp53, PTEN gene, CDH1, STK11, ATM, CASP 8, BARD1, BRIP1, CHEK2. Tp53 is 
a tumor suppressor gene involved in Li-Fraumeni syndrome. Li-Fraumeni syndrome is 
associated with early onset of numerous cancers. Women with Li-Fraumeni syndrome 
have early onset of breast cancers along with numerous other cancers. Ataxia 
telangiectasia is an autosomal recessive syndrome. In  Ataxia  telangiectasia,  there  is  
100  fold  increase  in  risk of breast  cancer  .  It  is  an  autosomal  recessive  syndrome  
due  to  DNA  repair  defect.  Women  with  Cowden  disease  having  mutation  in  the  
PTEN  tumor  suppressor  gene  develop  breast  cancer  by  50  years  of  age. 
Alleles with low penetrance can also lead to breast cancer. Population with this allele 
will have lesser risk but the attributable risk is more. According to the breast cancer 
association, larger sample size is needed to verify the association of polymorphism in 
breast cancer. (29) 
Genetic  susceptibility by both mutations with high  and  low  penetrance  gene, interact 
with the environmental  factors and increase the  incidence  of  breast  cancer. 
 
 
IV. Other risk factors 
A. Benign  breast  diseases 
Benign breast diseases increase the risk of breast cancer. Among the benign breast 
diseases, the risk varies with atypia and without atypia. Also the menopausal status 
changes the risk of benign breast disease. Risk for breast cancer increases by 1.5 fold 
for women with benign breast disease without hyperplasia as compared to the normal 
population. Risk for breast cancer varies with hyperplastic breast disease with atypia 
and without atypia. Hyperplasia without atypia caries only 1.8 fold increase of breast 
cancer. Whereas hyperplasia with atypia have 2.6 fold increased  risk of breast cancer. 
Menopausal status also changes the risk of benign breast diseases. Premenopausal 
women with benign breast disease have more risk for breast cancer when compared to 
postmenopausal women. (30) 
B. Ionizing  radiation 
Ionizing radiation is also one of the risk factor for breast cancer. Epidemiological 
studies done on, women who survived in the atomic bomb explosion, women exposed 
to radiation for screening, diagnostic and therapeutic reasons provides information 
about the association of ionizing radiation and breast cancer. Relative risks for breast 
cancer vary from 1.2 -2.4.  Relative risk vary with total dosage of radiation exposed and 
the age at which women is exposed. Women exposed at an early age have more risk 
than the women exposed at her older age. (32). The risk of exposure to very low doses 
of ionizing radiation (incurred in occupational exposures) remains uncertain.    In 
screening mammography only low dose of radiation is used (200-400 mrad). Women 
who are screened by mammography are generally above 35 years. Since the association 
between the breast cancer and low dose radiation exposure in elderly women is very 
low, benefit risk ratio of screening mammography in older women is high.  
C. Mammographic  density 
Mammography is a useful screening tool for breast cancer. Mammographic 
density represents the epithelial and connective tissues of the breast whereas the 
radiolucency represents the breast fat. Mammographic density is a major risk factor for 
breast cancer. Women having highest mammographic density have 4-6 times more 
chances of developing breast cancer when compared to women with low 
mammographic density. (31) 
D. Socioeconomic  Status 
Socioeconomic status have a role in breast cancer. Women in low socioeconomic 
status have relatively lesser risk for breast cancer than in higher socioeconomic status. 
Prevalence of breast cancer is higher in well-developed countries than the developing 
countries. Breast cancer is more common among well educated women because of late 
age of first pregnancy, no or few children, frequent use of hormonal therapy and oral 
contraception. 
 
S.No. RISK  FACTOR COMPARISON  
CATEGORY 
RISK  
CATEGORY 
RELATIVE  
RISK 
1. Age  at  menarche 16  years Younger  than  
12  years 
1.3 
2. Age  at  
menopause 
45  to  54  years After  55  years 1.5 
3. Age  at  when  first  
child  born  alive 
Before  20  years Nulliparous  or  
older  than  30  
years 
1.9 
4. Benign  breast  
disease 
No  biopsy  or  fine  
needle  aspiration 
Any  benign  
disease 
1.5 
Proliferative  
disease 
2.0 
Atypical  
hyperplasia 
4.0 
5. Family  history   No  1st  degree  
relative  affected 
Mother  
affected 
1.7 
Two  first  
degree  relative  
affected 
5.0 
6. Obesity 10th  percentile 90th  percentile 1.2 
7. Alcohol  use Non  drinker Moderate  
drinker 
1.7 
8. Estrogen  
replacement  
therapy 
Never  used Current  use  >3  
years 
1.5 
 
Table 1: Risk factors for breast cancer and their relative risks (33) 
 
 
 
 
DIAGNOSTIC MODALITIES   
A. Mammography   
There are two types of mammography. They are screening mammography and 
diagnostic mammography. All women’s above 40 years, having risk factors or family 
history are screened using screening mammography. Later evaluation of breast cancer 
is done by diagnostic mammography. Diagnostic mammography is for the  
1. Patients  with  breast  symptoms  or  complaints  such  as  nipple  discharge  or  
a  palpable  mass 
2. Patient  who  had  abnormal  results  on  screening  mammography  or 
3. Patient  who  had  underwent  breast  conservation  therapy. 
The  diagnostic  examination  is  tailored  to  the  individual  patient  specific  
abnormalities. 
 
B. Digital  mammography  (Also  called  full-field  digital  mammography,  or  
FFDM)  –   
FDA recently approved a new technology named FFDM for screening and 
diagnosis of breast cancer. It is a digitalized procedure which capture the images. Then 
it is processed in a system and then viewed. 
C. BIRADS  diagnostic  categories  — 
Radiologist analyses the mammographic images, and classify findings into a 
final category. American college of radiology standardized the mammographic 
reporting and termed it as BIRADS-Breast Image Reporting And Data System. It has 
0-6 score. 
0-incomplete 
1-negative 
2-benign findings 
3-probably benign 
4-suspicious 
5-highly suspicious of malignancy 
6-known biopsy with proven malignancy.  
D. ULTRASONOGRAPHY   
Solid and cystic component of breast lesions can be identified using 
ultrasonography. If there is any suspicious for metastasis in nodes, ultrasound can be 
done to detect positive lymph nodes. Ultrasound guided FNAC and biopsy can be taken 
in suspicious areas of breast mass and also in the lymph nodes.   
E. BREAST  MRI   
Among all the investigations MRI has highest sensitivity. The sensitivity is 
between 88 and 100 percent. Contrast enhancement can be seen in MRI in case of breast 
cancer. Preoperative MRI will estimate the extent of disease very accurately than the 
conventional imaging. 
 
 
F. Fine  needle  aspiration  cytology 
Fine needle aspiration cytology is very simple, cost effective outpatient 
procedure. Within a day the diagnosis can be arrived. It helps to differentiate solid and 
cystic lesion. In case of cystic lesion it can be used as a therapeutic procedure. 
Combination of ultrasound, fine needle aspiration cytology and diagnostic 
mammography achieves 100% accuracy in diagnosing breast cancer. 
G. Biopsy 
Core Needle biopsy 
Core needle biopsy of breast lesion is taken using hollow needle. Procedure is 
low cost and has little complication and will not produce scar.   
Open biopsy 
Open biopsy is not routinely recommended for all patients. It is performed only 
in patients who are already investigated with imaging, FNAC and core needle biopsy.  
H. Morphology 
 GROSS 
  Invasive mammary carcinoma represents the prototype of breast carcinoma. It 
is usually firm, ill circumscribed, yellowish gray lesion and gritty to cut. Grossly 
stellate configuration can be seen. Stellate configuration is due to radiation of 
trabeculae through the surrounding parenchyma and infiltrating into the fat. In 
case of large tumor, areas of necrosis, hemorrhage and cystic degeneration can 
be seen. 
 
            Microscopy: 
 Microscopic patterns commonly seen in invasive mammary carcinoma 
are diffuse sheets, cords, nest and singly scattered individual malignant cells. 
Well-developed glandular/tubular differentiation can also be seen. Sometimes 
it is only, just detectable tiny focus or completely absent. Tumor cells generally 
vary in size and shape.  They are large, more  pleomorphic when compared to 
invasive lobular carcinoma. Malignant cells have large hyperchromatic, 
pleomorphic nuclei and prominent nucleoli. Mitotic figures are commonly 
seen. More than 60 % cases shows necrosis. Apocrine metaplasia, squamous 
metaplasia, clear cell changes can also be seen in few foci. The amount of 
stroma vary with scant stroma to more abundant dense, cellular and fibrotic. 
Identification of tumor cells become very difficult if there is abundant stroma. 
90 % of tumor shows bulk of elastic tissues. Grossly elastosis can give rise to 
chalky streaks. Elastosis involves mainly the wall of the ducts and the main 
vessels. 60% cases show calcification which can be either coarse or fine 
granules. Rarely psammoma bodies can also be seen. Interphase of tumor and 
stroma shows chronic inflammatory infiltrate.  
Artefactual retraction can mimic lymphatic invasion. Features suggestive of 
lymphatic  tumor  emboli  are : (1)  the  occurrence  of  the  area  in  question  
outside  the  margin  of  the  carcinoma,  (2)  the  fact  that  the  tumor  emboli  
do  not  conform  exactly  to  the  space  in  which  they  lie,  (3)  the  presence  
of  an  endothelial  cell  lining,  and  (4)  the  presence  of  blood  vessels  in  
the  immediate  vicinity. 
Immunohistochemically,  the  tumor  cells  show  reactivity  for  low  
molecular  weight  keratin  (particularly  types  8,  18,  and  19)  and  EMA , 
Mammaglobin  and  GCDFP-15. Mammaglobin is more sensitive but less 
specific when compared with GCDFP-15.  
Proliferative  Biomarkers   
Tumor with high  proliferative  index will respond well to chemotherapy.    The  main  
obstacles  to  use  proliferative  markers  are 
1.  Poor  standardization  of  detection  methods 
2.  Vaguely  defined  cutoff  values 
3.  Requirement  of  fresh  frozen  tissue 
Proliferative  biomarkers  are 
1. Measurement  of    cells  in  S  phase: 
 Unfavorable  prognosis  of  breast  cancer  patients  are  seen  when  S  phase  
fraction  is  assessed  by  fresh  or  frozen  material.  But  several  studies  done  to  
assess  the  prognostic  value  by  DNA  flow  cytometry  lacks  standardized  procedures,  
sufficient  power  and  predefined  cutoff  values.  There  is  also  high  tumor  
heterogeneity  of  the  S  phase  fraction.  Therefore  it  cannot  be  recommended  for  
routine  prognostic  assessment.  Another  disadvantage  of  this  method  is it requires  
large  quantity  of  tumor  material,  making  it  inappropriate  for  smaller  tumors  
identified  through  mammographic  screening. 
2. H-Thymidine  Labeling  Index 
 H-thymidine  labeling  index  was  one  of  the  proliferative  biomarker  used  in  
breast  cancer.  Cells  undergoing  DNA  replication  is  measured  by  H-thymidine  
uptake  using  autoradiography.  Thymidine  labeling  index  represents  ratio  between  
the  number  of  labeled  and  counted  cells.  A  similar  approach  uses  IHC  technique  
and  halogenated  analogue  -Bromodeoxyuridine.  Limitations  of  this  technique  are  
the  requirement  of  fresh  frozen  tissue,  the  time  required  to  complete  the  assay  
and  use  of  radioactive  tracers. 
3. Thymidine  Kinase   
Thymidine  kinase  activity  is  measured  by  radio  enzymatic  assay.  Thymidine  
kinase  is  an  enzyme  that  catalyzes  the  phosphorylation  of  deoxy thymidine  to  
deoxy thymidine  monophosphate.  Its  activity  is  highest  in  G1-G  translation  check  
point  and  then  reduced  in  G2  phase  of  cell  cycle.  In  breast  cancer,  the  fetal  
isoform  of  Thymidine  kinase  is  present  in  high  levels  in  the  cytoplasm  and  
regulates  the  cell  cycle. 
4. Ki67 
Ki67  is  a  nuclear  antigen  which  is  present  in  mid  G1,  S,  G2  and  the  
entire  M  Phase  of  the  cell  cycle.  Over  expression  of  Ki67  correlates  with  
proliferative  activity  metastases  and  overall  survival. 
 
 
5. MIB1 
Similar  to  Ki67,  MIB1  is  a  nuclear  antigen  that  can  be  labeled  using  
immunohistochemistry.  It  can  be  performed  on  formalin  fixed  and  paraffin  
embedded  tissue.  A  good  concordance  is  seen      between  Ki67  and  MIB1  
assessment. 
6. Cyclin  A 
Cyclins  are  proteins  that  regulate  cell  cycle.  Cyclin  A  is  expressed  mainly  in  
the  late  S,  G2  and  M  phases  of  the  cell  cycle.  It  has  been  associated  with  poor  
prognosis. 
7. Cyclin  E 
Cyclin  E  regulates  G1  phase  progression  and  entry  into  S  phase.  There  are  
two  different  proteins,  cyclin  E1  and  E2  that  are  coded  by  2  different  genes  
with  47%  homology.  Cyclin  E1  is  determined  by  immunohistochemistry,  Western  
Blot  and  RT-PCR.  Elevated  levels  of  cyclins  increases  risk  of  breast  cancer  
related  death. 
8. Cyclin  D1   
The  family  of  cyclin  D  consists  of  at least  three  different  cyclins  that  regulate  
progression  of  cell  cycle  into  G1  phase.  The  function  of  cyclin  D1  is  to  bind  
to  the  cyclin  dependent  kinases  4  &  6  and  phosphorylate  downstream  proteins.  
These  complexes  can  sequester  cyclin  D  kinase  inhibitors.  Cyclin  D1  acts  as  a  
cofactor  for  ER  alpha  in  a  ligand  independent  manner.  The  concentration  of  
Cyclin  D1  is   highest  during  mid  G1  phase  and  then  gradually  declines.  Over  
expression  of  cyclin  D1,  mRNA,  protein  and  amplification  to  account  15%  in  
breast  cancer.  They  are  found  to  be  associated  with  ER  positive  and  well  
differentiated  tumors.  The  most  common  method  of  detection  of  cyclin  D1  
expression  is  immunohistochemistry. 
9. p27 
p27  is  a  cyclin  dependent  kinase  inhibitor  that  acts  in  the  nucleus.  It  is  
mobilized  by  anti proliferative  signals,  such  as  cell  to  cell  contact  and  transforming  
growth  factor  beta.  It  can  be  assessed  by  immunohistochemistry.  In  majority  of  
the  studies  p27  was  positively  correlated  with  ER  expression  and  had  inverse  
correlation  with  the  grade.  In  BRCA1/2  mutated  tumors,  low  level  of  p27  are  
seen. 
10.   Topoisomerase  II  alpha 
Topoisomerase  II  are  DNA  binding  enzymes  with  nuclease,  helicase  and  ligase  
activity.  Topoisomerase  II  beta  is  not  cell  cycle  dependent  whereas  topoisomerase  
II  alpha  is  cell  cycle  dependent  and  is  highest  in  G2/M  transition.  Coamplification  
of  topoisomerase  II  and  Her-2  are  associated  with  increased  sensitivity  to  
anthracyclines.  It  is  also  used  as  a  prognostic  marker  for  overall  survival  of  
breast  cancer  patients  independent  of  therapy. 
 
 11.   Urokinase  plasminogen  activator  (uPA)  and  Plasminogen  activator  
inhibitor(PAI-1) 
uPA  and  PAI-1  levels  are  associated  with  breast  cancer  recurrence  and  
survival.  They  also  predict  the  hormone  therapy  and  specific  types  of  
chemotherapy  response. 
WHO CLASSIFICATION OF INVASIVE CARCINOMA OF THE BREAST -
2016 
 Invasive mammary carcinoma of no special type 
 Micro-invasive mammary carcinoma 
 Invasive mammary carcinoma with extensive intraductal component 
 Invasive mammary carcinoma with matrix production 
 Invasive mammary carcinoma, no special type, with lobular features 
 Invasive lobular carcinoma with pleomorphic features 
 Invasive lobular carcinoma, alveolar variant 
 Invasive carcinoma with ductal and lobular features 
 Invasive mammary carcinoma with mucinous features 
 Invasive mammary carcinoma with tubular features 
 Invasive mammary carcinoma,tubulo-lobular variant 
 Invasive mammary carcinoma with cribriform features 
 Invasive carcinoma with micro papillary features 
Invasive solid papillary carcinoma 
Encapsulated papillary carcinoma 
Invasive mammary carcinoma with medullary features 
Metaplastic carcinoma 
Adenoid cystic carcinoma 
Secretory carcinoma 
Invasive mammary carcinoma with neuro endocrine features 
Invasive carcinoma with signet ring cell features 
Invasive carcinoma with clear cell features 
Invasive carcinoma type cannot be determined. 
No residual invasive carcinoma after presurgical therapy 
STAGING  OF  BREAST  CANCER   
TNM  staging  of  tumor  is  based  on  size  of  primary  tumor,  regional  lymph  
node  and  distant  metastasis. 
American  Joint  Committee  on  Cancer  (AJCC)  staging  system  provides  guidelines  
for  breast  cancer  patient  according  to  the  prognostic  status.  The  AJCC  has  
designed  staging  by  TNM  classification.(34) 
TNM  STAGING 
Primary  tumor  (T): 
 TX:  Primary  tumor  cannot  be  assessed 
 T0:  No  evidence  of  primary  tumor 
 Tis:  Carcinoma  in  situ;  DCIS/LCIS/Paget’s 
 T1:  Tumor  size  (2  cm  or  less). 
 T1mi:  less  than  0.1cm  micro invasion  
 T1a:  more  than  0.1  cm  but  less  than  0.5  cm  
 T1b:  more  than  0.5cm  but  less  than  1 cm   
 T1c:  more  than  1cm  but  less  than  2  cm   
 T2:  Tumor  size  2-5  cm   
 T3:  Tumor  size  more  than  5cm   
 T4:  Tumor  of  any  size  with  direct  extension  to  chest  wall  and  or  to  the  skin  
(ulceration  or  skin  nodules) 
 T4a:  Extension  to  chest  wall,  not  including  only  pectoralis  muscle  
invasion/adherence 
 T4b:  Ulceration  and/or  ipsilateral  satellite  skin  nodules  and/or  edema 
 T4c:  Both  of  the  above  (T4a  and  T4b) 
 T4d:  Inflammatory  carcinoma 
Regional  lymph  nodes  (N) 
 NX:    (RLN)  cannot  be  assessed 
 N0:  No  regional  lymph  node  metastasis 
 pN0(i-):  No  ‘RLN’  metastasis  identified  histologically,  negative  IHC 
 pN0(i+):  Malignant  cells  in  ‘RLN’  less  than  0.2  mm  (detected  by  H&E  or  IHC) 
 pN0(mol-):  No  RLN  metastasis  histologically,  negative  molecular  findings(RT-
PCR) 
 pN0(mol+):  Positive  molecular  findings  (RT-PCR)  but  no  RLN  metastasis  
detected  histologically  or  by  IHC 
 pN1mi:  Micrometastasis  (greater  than  0.2  mm  and  /or  more  than  200  cells  but  
none  greater  than  2.0mm) 
 pN1a:  Metastases  in  1  to  3  axillary  lymph  nodes,  at least  one  metastases  greater  
than  2.0  mm 
pN1b:  Metastases  in  internal  mammary  nodes  with  micro metastases  or  macro 
metastases  detected  by  sentinel  lymph  node  biopsy  but  not  detected  clinically 
pN1c:  Metastases  in  1  to  3  lymph  nodes  and  in  internal  mammary  nodes  with  
micro metastases  or  macro metastases  detected  by  sentinel  lymph  node  biopsy  but  
not  detected  clinically 
pN2a:  Metastases  in  4-9  axillary  lymph  nodes  (at least  one  tumor  deposit  greater  
than  2.0  mm). 
pN2b:  Metastases  in  clinically  detected  internal  mammary  nodes  and  in  the  
absence  of  axillary  LN  metastasis 
pN3a:  Metastases  in  10  or  more  axillary  lymph  nodes  (at  least  one  tumor  deposit  
greater  than  2.0mm);or  metastases  to  the  infraclavicular  (level  3  axillary  lymph  
nodes  and  in  internal  mammary  lymph  nodes)  nodes 
pN3b:  Metastases  in  clinically  detected  ipsilateral  internal  mammary  lymph  nodes 
Distant  metastases  (M): 
M1:  Distant  detectable  metastasis  as  histologically  proven  larger  than  0.2mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
STAGING: 
Stage  groupings: 
Stage  0 
 Tis,N0,M0 
Stage  1 
 T1,N0,M0  
T1  include  T1mic 
Stage  2A 
 T0,N1,M0 
 T1,N1,M0 
 T2,N0,M0 
 T1  includes  Tmic.  The  
prognosis  of  patient  with  pN1a  disease  
is  similar  to  that  of  pN0  disease 
Stage  2B 
 T2,N1,M0 
 T3,N0,M0 
Stage  3A 
 T0,N2,M0 
 T1*,N2,M0 
 T2,N2,MO 
 T3,N1,M0 
 T3,N2,M0 
 *T1  includes  T1  mic 
Stage  3b 
 T4,Any  N,M0 
 Any  T,N3,M0 
Stage  4 
 Any  T,  Any  N,  M1 
 
 
Table 2 : Staging of breast cancer 
HISTOLOGICAL  GRADING  OF  BREAST  CANCER 
Histologic  grading  based  on 
1. Tubule  formation,  2.  Nuclear  pleomorphism,  3.  Number  of  mitosis 
1.Tubule  formation 
>75% 
10  to  75% 
<10% 
2.  Nuclear  pleomorphism 
 
Small  uniform  cells                                                                                                         
 
Moderate  increase  in  size  and  variation 
 
Marked  variation 
3.Number  of  Mitosis  (Microscope  Nikon  40x  objective) 
Up to  7/  10  hpf 
 
8-14/  10  hpf 
 
More  than  or  equal  to  15/  10  hpf 
 
Score 
1 
2 
3 
 
 
1 
 
2 
3 
 
1 
 
2 
 
3 
Table 3 : Modified  Bloom  Richardson    histologic  scoring  criteria  (35) 
GRADE DESCRIPTION   SCORE 
Grade  1 Well  differentiated  breast  epithelial  cells. 
Cells  generally  appear  normal  not  growing  rapidly.  Cells  
arranged  in  small  tubules. 
3,4,5 
Grade  2 Moderately  differentiated  breast  epithelial  cells.  Have  
characteristics  between  Grade  1  &  3  tumors 
6,7 
Grade  3 Poorly  differentiated  breast  epithelial  cells.  Cells  do  not  
appear  normal  and  tend  to  grow  and  spread  aggressively. 
8,9 
Table 4 : Nottingham  Modification  of  Bloom  Richardson  grading  system 
Estrogen  receptor 
The  breast  cancer  markers  that  are  most  important  in  determining  therapy  
are  estrogen  and  progesterone  receptor  and  HER-2/neu 
Estrogen  receptors  are  members  of  the  steroid  receptor  superfamily.  Two  
isoforms  of  ER  such  as  ER  alpha  and  ER  beta  have  been  identified.  The  
knowledge  about  most  of  ER  activity  and  function  has  been  obtained  from  ER  
alpha  studies.  Much  less  is  known  about  ER  beta  (36). 
The  ER  is  a  nuclear  transcription  factor  that  regulates  the  expression  of  
number  of  genes  involved  in  regulation  of  transcription  and  differentiation.  
Binding  of  ligand  to  ER  results  in  a  ligand-ER  complex  that  subsequently  induces  
an  ER  conformational  change,  dissociation  of  chaperones  such  as  hsp90  and  
hsp70  and  receptor  dimerization.  Activated  ER  dimers  can  bind  to  the  Estrogen  
receptor  elements  (ERE)  of  target  genes  and  regulate  their  transcription.  Some  
nuclear  proteins  interact  with  ER  and  function  as  coactivators  or  corepressors  of  
ER. 
Due  to  the  important  role  played  by  ER  in  breast  carcinoma  progression,  
development  of  agents  which  can  be  specific  to  target  ER  or  its  ligands  is  
therefore  an  important  strategy  for  breast  carcinoma  treatment.  Endocrine  therapies  
applied  include  depletion  of  the  ligand,  estrogen,  steroidal  antiestrogens  that  
destroy  ER  and  selective  ER  modulators. 
Hormone  resistance  which  can  be  denovo  or  acquired  is  a  feature  of  some  
breast  carcinomas.  30%  of  breast  cancers  lack  ER  gene  expression  approximately.  
Tumor  lacking  ER  protein  are  usually  associated  with  higher  growth  rate,  
poor  differentiation  and  worse  clinical  outcome.  Therefore  ER  expression  can  
be  used  as  a  prognostic  factor  for  early  breast  carcinoma  patients.  Genetic  changes  
that  account  for  the  loss  of  ER  in  breast  cancer  include  deletions,  insertions,  
point  mutations  or  rearrangement  of  ER  gene. 
 
 
 
 
Tissue  distribution  of  ERs: 
The  distribution  of  two  receptors  overlap  in  breast,  endometrium,  bone,  
prostate,  epididymis,  central  and  peripheral  nervous  system  (37). 
Liver  and  white  adipose  tissue  show  ER  alpha  expression  alone. 
Kidney,  Bladder,  Intestine,  ovary  show  only  ER  beta  expression  alone. 
Progesterone  receptor: 
 Positive  receptor  status  in  breast  carcinoma  is  associated  with  a  good  
prognosis  as  well  as  better  response  to  hormonal  therapy,  better  survival  and  
long  disease  free  period(38).  IGF-I  (insulin like  growth  factor-1)  inhibits  expression  
of  progesterone  receptor  in  breast  carcinoma  cells  via  the  phosphatidylinositol  3-
kinase/akt/mammalian  target  of  the  rapamycin  pathway.  If  there  is  low  expression  
of  PR,  it  indicates  activated  growth  factor  signaling  in  breast  carcinoma  cells  
(39).  Hence  low  expression  of  progesterone  receptor  may  serve  as  an  indicator  
of  activated  growth  factor  signaling  in  breast  carcinoma  cells,  and  it  represents  
aggressive  tumor  phenotype  which  is  resistant  to  hormonal  therapy  (39).  PR  
expression can   define  a  subpopulation  of  breast  cancer  patients  who  may  be  
strongly  dependent  on  hormone  receptor-associated  growth,  and  so  superior  
response  to  hormone  therapy  (40). 
 PR  bind  hormones  that  exert  their  effects  in  the  nucleus.  Nuclear  
immunostaining  for  both  estrogen  and  progesterone  receptors  are  normally  
demonstrated  on  breast  acini,  which  serve  as  internal  controls  for  the  testing  
procedure  (Figures1,2).  In  general,  approximately  15%  to  20%  of  the  luminal  
epithelial  cells  in  a  duct  or  lobule  stain  with  ER  and  PR.  However,  nuclear  
staining  in  normal  breast  tissue  may  vary  with  the  menstrual  cycle  and  is  
heterogeneous  (41)  
In  carcinomas  of  the  breast,  most  PR-positive  tumors  are  also  ER  positive,  and  
ER-negative,  PR  positive  tumors  account  for  fewer  than  1%  of  all  breast  cancers.  
In  general,  patients  with  positive  PRs  have  a  significantly  longer  disease-free  
survival  than  patients  who  are  PR  negative 
HER2neu: 
 The  ERBB2  (formerly  HER2)  gene  was  originally  called  NEU  because  it  
was  first  derived  from  rat  neuroblastoma/  glioblastoma  cell  lines.  Coussens  and  
colleagues  (42)  named  it  HER2  because  its  primary  sequence  was  very  similar  
to  human  epidermal  growth  factor  receptor  (EGFR,  ERBB,  or  ERBB1).  Semba  
and  associates  (43)  independently  identified  an  ERBB-related  but  distinct  gene,  
which  they  named  ERBB2.  Di  Fiore  and  colleagues  (44)  indicated  that  both  
NEU  and  HER2  were  the  same  as  ERBB2,  and  Akiyama  and  associates  (45)  
precipitated  the  ERBB2  gene  product  from  adenocarcinoma  cells  and  demonstrated  
it  to  be  a  185-kD  glycoprotein  with  tyrosine  kinase  activity 
 Clinical  significance  of  HER2  gene  amplification  was  shown  in  breast  
cancer,  in  the  year  1987  (2  years  after  its  discovery)  (46).  15%  to  20%  of  breast  
cancers  approximately  demonstrate  HER2  gene  amplification  and/or  protein  
overexpression  (47,48).  HER2-positive  breast  cancer  patients  have  a  worse  
prognosis  without  any  adjuvant  systemic  therapy.  They  have  higher  rates  of  
recurrence  and  mortality,  so  it  clearly  demonstrates  significant  prognosis. 
An  even  more  important  aspect  of  determining  HER2  status  is  its  role  as  a  
predictive  factor.  HER2  positivity  is  predictive  of  response  to  anthracycline-  and  
taxane-based  therapies,  although  the  benefits  derived  from  non-anthracyclines  and  
non-taxane  therapies  may  be  inferior  (49-53).  It  is  also  important  to  note  that  
HER2-  positive  tumors  generally  show  relative  resistance  to  all  endocrine  
therapies;  however,  this  effect  may  be  more  toward  selective  endocrine  receptor  
modulators,  such  as  tamoxifen,  and  less  likely  toward  estrogen-depletion  agents,  
such  as  aromatase  inhibitors  (54,55).HER2neu  takes  up  membranous  pattern  of  
staining  (Figure  3) 
 
 
 
 
 
 
 
 
 
Molecular  pathways: 
 FIVE  MAJOR  PATTERNS  OF  GENE  EXPRESSION  IN  NST  
GROUP: 
1. Luminal  A  (40%  to  55%  of  NST  cancers): 
 ER  positive,  HER2  neu  negative 
 Majority  are  well  or  moderately  differentiated,  occur  in  
postmenopausal  women 
 Slow  growing,  respond  well  to  hormonal  treatment 
 But  only  a  small  number  will  respond  to  standard  chemotherapy 
2. Luminal  B  (15%  to  20%  of  NST  cancers): 
 ER  positive,  also  often  HER2  neu  positive 
 Usually  high  grade 
 Responds  less  to  hormonal  therapy,  but  better  to  chemotherapy 
3. Normal  breast–like  (6%  to  10%  of  NST  cancers): 
 ER  positive,  HER2  neu  negative 
 Usually  well  differentiated 
4. Basal-like  (13%  to  25%  of  NST  cancers): 
 Triple  negative 
 Express  basal  markers(basal  keratins,  p63,  P-cadherin,  laminin) 
 Includes  medullary  carcinoma,  metaplastic  carcinoma,  carcinomas  
with  central  fibrotic  focus 
 Aggressive  with  poor  prognosis 
 15-20%  respond  to  chemotherapy 
5. HER2  positive  (7%  to  12%  of  NST  cancers): 
 ER  negative  but  HER2  neu  overexpressed 
 overexpression  is  due  to  amplification  of  the  segment  of  DNA  on  
17q21 
 Poorly  differentiated,  associated  with  high  degree  of  brain  metastasis 
6. Luminal  A  (40%  to  55%  of  NST  cancers): 
 ER  positive,  HER2  neu  negative 
 Majority  are  well  or  moderately  differentiated,  occur  in  
postmenopausal  women 
 Slow  growing,  respond  well  to  hormonal  treatment 
 But  only  a  small  number  will  respond  to  standard  chemotherapy 
7. Luminal  B  (15%  to  20%  of  NST  cancers): 
 ER  positive,  also  often  HER2  neu  positive 
 Usually  high  grade 
 Responds  less  to  hormonal  therapy,  but  better  to  chemotherapy 
8. Normal  breast–like  (6%  to  10%  of  NST  cancers): 
 ER  positive,  HER2  neu  negative 
 Usually  well  differentiated 
9. Basal-like  (13%  to  25%  of  NST  cancers): 
 Triple  negative 
 Express  basal  markers(basal  keratins,  p63,  P-cadherin,  laminin) 
 Includes  medullary  carcinoma,  metaplastic  carcinoma,  carcinomas  
with  central  fibrotic  focus 
 Aggressive  with  poor  prognosis 
 15-20%  respond  to  chemotherapy 
10. HER2  positive  (7%  to  12%  of  NST  cancers): 
 ER  negative  but  HER2  neu  overexpressed 
 overexpression  is  due  to  amplification  of  the  segment  of  DNA  on  
17q21 
 Poorly  differentiated,  associated  with  high  degree  of  brain  metastasis 
 
 
 
 
 
 
 
 
 
 
MAST CELLS 
 In 1878, Paul Ehrlich was the first to describe mast cells in his doctoral thesis. 
He also described about their granules and special staining characters. 
He initially thought that these cells feed the surrounding cells and named them as 
“mastzellen” a German word which denotes “breast”. He also found the histo chemical 
reaction of aniline dyes on mast cells. He emphasized that the mast cells should be 
identified by their staining characters, and not just by their size and shape.(56) 
  Mast cells are a part of immune system. They stay in the blood for long time. They 
appear in all organs and connective tissue which have good blood circulation. Avascular 
tissues like cartilage, mineralized bone and cornea are devoid of mast cells. In the solid 
organs mast cells are found in the tissue close to the blood vessels.(Figure 4) It is also 
seen in organs like gastro-intestinal tract, lungs and skin which forms interface between 
the external environment and the internal environmental. Organs which are more prone 
to trauma like nose, mouth and feet have large number of mast cells. This explains why 
mast cells are considered to be a part of immune system. 
  Masts cells were initially considered to be related to basophils. Though both originate 
from the same hematopoietic stem cells, they diverge immediately after that. Basophils 
become entirely mature before leaving the bone marrow but mast cells are not. They 
are immature when they leave the bone marrow. 
In  normal micro environment mature mast cells are not seen in the circulation. Under 
the influence of stem cell factor and various cytokines immature mast cells mature and 
migrate to their respective sites. 
TYPES OF MAST CELLS: 
1. MAST CELL- TRYPTASE 
2. MAST CELL-TYPTASE-CHYMASE 
3. MAST CELL-CHYMASE 
MAST CELL-TRYPTASE (MCT): 
 They are immune associated usually T cell and contains tryptase. They are found in the 
mucosa of the gastrointestinal tract and in the respiratory system.  
MAST CELL-TRYPTASE-CHYMASE (MCTC):  
They are found in the connective tissue, skin,breast,heart,lymph nodes, conjunctiva of 
the eye and in the synovium. They contains chymase and tryptase. 
MAST CELL-CHYMASE (MCC):  
These mast cells contains only chymase and are found in the submucosa of the stomach, 
intestine and colon. Thus the mast cells are characterized based on the tissue, location 
and the enzymes present. 
 
MAST CELL MORPHOLOGY: 
Mast cells are round to oval in shape. It is about 8 to 20 micrometer in diameter. It has 
abundant cytoplasm with 50-200 large secretory granules. Size of the granules is about 
1.5 micrometer in diameter. Secretory granules contains more than 12 types of proteins. 
MEDIATORS STORED IN MAST CELLS: 
AMINES: Histamine, polyamines 
PROTEOGLYCANS: Heparin, chondratin sulfates, serglycin 
PROTEASE 
TRYPTASE: Tryptase-alpha, beta -one, two, three, gamma, delta, chymase-1, 
Cathepsin G, Granzyme B, Carboxypeptidase A 3 
LYZOSOMAL ENZYMES: Beta–Glucuronidase, beta 
Hexosaminidase, arylsulfatase. 
CYTOKINES: TNF, SCF, IL-4, b-FGF 
                Mast cell activation is measured by monitoring the release of granules from 
the cytoplasm known as degranulation. Release of mediators like beta-hexosaminidase, 
histamine or tryptase is taken into account for activation of mast cells.  
 
Mediators of mast cells can be broadly divided into pre-stored mediators and granule-
derived mediators. Release of pre-stored mediators is an early and rapid event. Within 
15-90 seconds large amount of stored granules of histamine are released. Thus the rapid 
release of pre-stored mediators not only enable rapid anaphylactic reactions but also 
starts recruiting leucocytes to the site of pathogen entry, activates innate immune 
processes and inflammation. Granule derived mediators are associated with long term 
responses like wound healing and tissue remodeling processes.(57)   Raposo et al (58) 
distinguished 3 types of granules in mast cells. They are listed in the below table.5. 
MAST CELL GRANULE BIOGENESIS: 
Small fusogenic granules are called unit granules. Regulated fusion of unit granules 
results in the biogenesis of mast cell granules. (59). Early unit granules are found in the 
Trans Golgi region and fuse together to generate progranules. Progranules are found in 
the outermost Golgi cisternae and rough endoplasmic reticulum. Volumes of 
TYPES CONTENTS ASSOCIATEDPROTEINS 
Type I Cathepsin D 
Beta-Hexosaminidase 
LAMP-2 
MHC-II 
M6PR 
LAMP-1and 2 
Type II Histamine 
Serotonin 
Beta-Hexosaminidase 
VAMP-8 
MHC-II 
M6PR 
LAMP-1and 2 
Type III TNF 
Serotonin 
Beta-Hexosaminidase 
VAMP-8 
M6PR 
progranules are the multiples of unit granules. Progranules are immature granules and 
they become mature by fusion process with other mature or immature granules. 
Condensation is a process which reduces the granule volume and organizes the contents. 
 
Figure 5 –Depicts the formation of granules in mast cells. 
Release of the granules occur by 2 processes. They are exocytosis and piecemeal 
degranulation. 
EXOCYTOSIS: It is responsible for the anaphylactic shock and severe allergic 
reactions. Hence it is also known as anaphylactic degranulation. Large amount of 
granules will suddenly bind with each other and to the cell membrane. This in turn leads 
to the opening of channels in the mast cells and allow quick release of the granules with 
its content. 
PIECEMEAL DEGRANULATION: It is commonly seen in chronic inflammation 
and in carcinomas. It is a slow process. Only some of the granules are released slowly 
without making channels to the exterior. 
 
FIGURE -6 Depicts the mode of release of mast cell granules 
MOLECULES INVOLVED IN MAST CELL GRANULES BIOGENESIS 
There are several molecules involved in biogenesis of  mast cell granules. They are 
listed in below  table .6 .(57) 
PROTEIN FUNCTION 
Histidine decarboxylase Promotes granule maturation 
Synaptotagmins Membrane trafficking 
Secretogranin III Regulates membrane dynamics of 
secretory vesicles 
Chromogranin A Binds Secretogranin and promotes 
granule biogenesis 
Clathrin Involved in compensatory 
endocytosis following exocytosis 
Polyamines Regulate granule cargo storage and 
granule morphology 
Vesicular monoamine transporter 2 Transport of monoamine into 
secretory granules 
Serglycin Retention of protease in granules 
Nuclear receptor 4a3 Modifies granule contents 
 
 
 
 
 
 
MOLECULES INVOLVED IN MAST CELL DEGRANULATION 
There are several molecules involved in mast cell degranulation. They are listed in the 
below mentioned table 7.(57) 
PROTEIN FUNCTION 
Munc 13-4 Positively regulates degranulation 
Munc 18-2 Controversial in degranulation, 
interacts with syntaxin-3 
Complexin II Enhances Ca 2+ mobilization and 
degranulation 
VAMP-8 Controversial in degranulation 
Synaptotagmin II Controversial in degranulation 
Rab3A Controversial in degranulation 
Rab3d Negatively regulates degranulation 
Rab27a Negatively regulates degranulation 
Rac 1 Positively regulates degranulation 
Rac 2 Positively regulates degranulation, 
regulates Ca 2+ mobilization 
Cdc42 Positively regulates degranulation, 
interacts with PLC gamma 1 
DOCK5 Positively regulates degranulation, 
regulates microtubule dynamics 
 
PHYSIOLOGICAL ROLES OF MAST CELLS 
Mast cells are involved in variety of physiological functions. They are angiogenesis, 
vasodilation, parasite and bacterial elimination. They also regulates the function of 
macrophages, dendritic cells, T cells, B-cells, endothelial cells, eosinophils and 
epithelial cells. Mast cell play a major role in regulating bone growth , remodeling and 
homeostasis of minerals.(60). 
ANGIOGENESIS: 
Mast cells play a significant role in angiogenesis. They secrete pro-angiogenic  factors 
like bFGF, VEGF, TNF –alpha, TGF –beta and IL-8. They also release heparin and 
protease which in turn release pro-angiogenic factors. Histamine from the mast cells 
increases the permeability of the microvasculature. Evidence show that mast cells also 
enhances angiogenesis in growth of the tumor.(61) 
DISEASES INVOLVING MAST CELLS 
Mast cells are implicated in the following disease process. They are allergies, 
autoimmune diseases, interstitial cystitis, mast cell tumors. 
 ALLERGIES: 
It is a best example for localized mast cell degranulation. In the skin it can produce 
eczema, itching. Runny nose, runny eyes, asthma. etc. also produced by mast cell 
degranulation. Systemic mast cell degranulation can lead to anaphylaxis. 
AUTOIMMUNE DISEASE: 
Mast cells recruit additional inflammatory cells in autoimmune diseases like bullous 
pemphigoid, multiple sclerosis and rheumatoid arthritis. 
INTERSTITIAL CYSTITIS: 
Increase of mast cells around the nerves of the bladder will cause pain and interstitial 
cystitis. 
Mast cells are also implicated in atherosclerosis, endometriosis and 
cardiomyopathy.(56) 
MAST CELL TUMOURS: 
Mastocytosis is  a rare tumor caused by mast cells and CD 34 precursor of mast 
cells.(Figure.7) .It is commonly seen cutaneous. Presents with red spots and hives. 
Involvement of organs leads to systemic mastocytosis. In systemic mastocytosis bone 
marrow, liver , spleen, lymph nodes and GI tract can be involved. People having either 
cutaneous or systemic mastocytosis have severe allergic reactions day to day leading to 
itching, hives and anaphylactic response. Other mast cell cancers are mast cell leukemia 
and mast cell sarcoma. 
ROLE OF MAST CELL IN CANCER: 
Interaction between microenvironment and cancer cells are numerous . They can lead 
to either progression of tumor or it can be regressive. Microenvironment around the 
tumor composed of stromal cells ,cells of innate and adaptive immunity. It creates a 
barrier to immune response against cancer and an emerging target for cancer 
immunotherapies.(62). Relation of mast cells and cancer is diverse and is not fully 
understood. Currently it is evident that mast cell influence cancer angiogenesis, 
invasion and immune suppression.(62).  
Large number of studies were done to identify the role of tumor associated mast 
cells in varies cancer. Studies show that TAMC(Tumor Associated Mast Cell) are 
functional(can either promote or suppress the tumor growth) in some cancers and non-
functional(inert) in some cancers.(63) 
Cancers, were mast cells play protumorigenic are Angioimmunoblastic T cell 
lymphoma, Bladder carcinoma, colorectal cancer, cutaneous lymphoma, esophageal 
carcinoma, follicular lymphoma, gastric carcinoma, hepatocellular carcinoma, 
Hodgkin’s lymphoma, lung cancer, malignant pleural effusion, malignant melanoma, 
merkel cell carcinoma, pancreatic carcinoma, plasmacytoma, prostatic carcinoma, 
thyroid cancer and splenic marginal zone lymphoma.(63) 
Cancers were mast cells play anti tumorigenic role are Diffuse large B cell lymphoma, 
Breast cancer, non-small cell lung cancer, ovarian cancer.(63). 
In breast cancers mast cells always play anti tumorigenic role.(64). 
 
ROLE OF TAMCs IN TUMOR ANGIOGENESIS AND 
LYMPHANGIOGENESIS: 
    Angiogenesis is essential for supplying growing cancer tissue with nutrients 
and oxygen. Lymph angiogenesis is essential for the development of metastases. 
Folkman proposed that mast cells and macrophages are attracted by chemotactic factors 
produced by the tumor cells and act as a source of proangiogenic factors.(65). Mast cell 
produces proangiogenic factors like VEGF-A,VEGF-B,FGF-2 and lymphangiogenic 
factors like VEGF –C and VEGF –D.  VEGFs are chemotactic for mast cells which 
indicates they are both the source and target.(66) 
     Mast cells also produce matrix metalloproteinases (MMP-9), 
proteases(tryptase and chymase) which digests the extracellular matrix and favors the 
tumor implantation in aberrant microenvironment.(67). 
Epithelial to mesenchymal transition(EMT) makes tumor cells to gain metastatic 
features and also drug resistance to chemotherapy.(68). 
 
 
 
 
MAST CELLS IN BREAST: 
During breast development mast cell sustains proliferation of ductal cells , helps 
in tissue remodeling, angiogenesis through the release of protease.(69). At the same 
time mast cells play a role in tumor tissue rearrangement by favoring invasion and 
metastatization. 
Stromal infiltration of mast cells even in very minimal number is a very good 
prognostic marker in mammary carcinoma.(70) 
Mast cells regress the tumour growth in breast cancer by releasing mediators 
like ROS and TNF-alpha. These mediators are cytotoxic to the tumour cells directly. 
Mast cells also release heparin,IL-9 which in turn stimulate dentritic cell maturation 
which are indirectly cytotoxic to the tumour cells.(63) 
MAST CELLS –POTENTIAL THERAPEUTIC TARGET IN CANCER 
Several drugs are under trial to limit the tumor growth by targeting mast cells. In 
a study done by Soucek L, Lawlor ER et all it is found that sodium cromoglycate-
cromolyn (drug that prevents the release of mediators of mast cell during 
degranulation) induced tumor cell apoptosis by hypoxia and clotting in blood 
vessels.(71) 
TRANILAST-AND BREAST CANCER 
          Tranilast is a drug which inhibits  mast cell tryptase and commonly used in 
inflammatory and allergic pathways. Now it gained considerable attraction due to its 
antitumor potential. This drug is approved in Korea and japan from 1982 for topical and 
systemic application bronchial asthma, atopic dermatitis, allergic conjunctivitis and 
keloids. Both in vivo and in vitro Tranilast is now reported to inhibit the VEGF induced 
angiogenesis ,concomitant with inhibitory effect of degranulation of mast cells.(72) 
The below mentioned table. 8 depicts the various studies of tranilast on breast cancer. 
AUTHOR DRUG TUMOR 
TARGET 
MOLECULAR 
MECHANISM 
RESULTS 
Chakrabarti et 
al. 2009(73) 
Tranilast Mouse,rat,human 
breast cancer 
 (1) down-
regulation of 
TGF-𝛽 pathway 
(2) inhibition of 
MAPK 
pathway 
 
inhibition of 
tumor cell 
proliferation, 
angiogenesis, 
apoptosis, 
migration 
 
Subramaniam 
et al.  
2010(74) 
Tranilast mouse breast 
cancer cell 
line (4T1) 
 
(1) down-
regulation of 
TGF-𝛽 pathway 
(2) induction 
cell arrest 
in the G0/G1 
transition, 
PARP cleavage, 
AKT1 
phosphorylation 
(3) up-
regulation of 
p53 
inhibition of 
tumor cell 
proliferation, 
angiogenesis, 
apoptosis, 
migration 
(4) reduction of 
ERK1/2 
phosphorylation 
 
Nie et al.  
1997 (75) 
 
Tranilast breast cancer cell 
lines 
(MCF-7) 
 
induction cell 
arrest in 
the G0/G1 
transition 
decrease of 
tumor growth 
 
Hall et al. 
2010 (76) 
 
Tranilast several human 
breast 
cancer cell lines 
 
agonizing ARH 
with 
down-regulation 
of 
TGF-𝛽 and NF-
𝜅B 
pathways 
 
(1) induction 
of apoptosis 
(2) inhibition 
of 
angiogenesis, 
cell growth, 
invasion and 
metastasis 
 
 
Zhang et al. 
2009 (77) 
  
tranilast several ER 
negative human 
breast cancer cell 
lines 
 
agonizing ARH 
with 
down-regulation 
of 
TGF-𝛽 and NF-
𝜅B 
pathways 
(1) induction 
of apoptosis 
(2) inhibition 
of 
angiogenesis, 
cell growth, 
invasion and 
metastasis 
  
Subramaniam 
et al.  
2011 (78) 
 
 
 
 
tranilast human breast 
cancer cell 
lines (triple 
positive-BT-474, 
triple 
negative-MDA-
MB-231 
1) up-regulation 
of p53 
(2) induction 
cell arrest 
in the G0/G1 
transition, 
AKT1 and 
ERK2 
phosphorylation, 
PARP-cleavage 
product 
 
induction of 
apoptosis, 
tumor 
growth, 
migration 
 
 
 
MAST CELL IDENTIFICATION BY USING GIEMSA 
Giemsa is a romanowsky dye which contains methylene blue and eosin. 
Methylene blue in an alkaline environment stains mast cells metachromatic. 
Metachromatic reaction is defined as the capacity of a stain to give different color to 
selected tissue component. This is attributed by a change in absorption peak with 
different concentration of stain. It requires the presence of anionic group in tissue 
component. Mast cell granules naturally induce metachromatic property. 
PROCEDURE OF GIEMSA STAIN : 
Tissue is fixed in 10 % Buffered Neutral Formalin. Sections are cut at 3 microns 
thickness. Slides are deparaffinized and hydrated in distilled water. Working giemsa 
solution is made by diluting ready-made giemsa solution with distilled water in 1:20 
ratio. Slides are dipped in working giemsa solution for 30 mins. It is then differentiated 
in 1 % acetic acid solution for 3 seconds. Then rinsed in distilled water and dehydrated 
and mounted.  Mast cells will show violet purple metachromatic stain. 
ER , PR, HER 2 NEU BY IMMUNOHISTOCHEMISTRY 
Immunohistochemistry  involves  two  disciplines,  immunology  and  histology.  
Immunohistochemistry  is  used  to  determine  expression  of  particular  antigen  and  
its  microanatomic  location  in  the  tissue. 
 Immunohistochemistry  was  started  in  1940  when  Coons  developed  an  
immunofluorescence  technique  to  detect  corresponding  antigen  in  frozen  sections. 
Taylor  and  colleagues  in  1974  showed  it  was  possible  to  demonstrate  
antigens  in  routinely  processed  tissue.  Antigen  retrieval  technique  was  introduced  
by  Shi  and  associates  in  1991.  Antigen  retrieval  technique  is  a  simple  method  
that  involves  paraffin  processed  sections  at  high  temperature  before  IHC  staining. 
The  use  of  antibody  in  IHC  depends  on  the  sensitivity  and  specificity  of  
the  antigen  –antibody  reaction. 
Blocking  non-specific  background  staining 
   Background  staining  is  due  to  either  nonspecific  binding  or  presence  of  
endogenous  enzymes.  Nonspecific  binding  with  polyclonal  primary  antibody  is  
minimized  by  pre  incubating  sections  with  serum  from  same  species  on  optimal  
working  dilution. 
Endogenous  enzymes  such  as  peroxidase  seen  in  normal  and  neoplastic  
tissues  is  abolished  by  peroxidase  blocking  or  by  using  alternate  systems  such  
as  immunogold  technique. 
Methods  suggested  to  overcome  endogenous  activity  include  incubation  in  
methanol  containing  0.5%  hydrogen  peroxide  for  10  minutes  at  room  temperature  
(almost  complete  abolition  of  endogenous  peroxidase  activity).  Endogenous  
alkaline  phosphatase  is  blocked  by  addition  of  0.1M  concentration  of  levamisole  
to  the  enzyme  substrate  solution. 
Detection  systems: 
 Antibodies  are  labeled  or  flagged  by  some  method  to  permit  visualization.  
These  includes  fluorescent  substances,  enzymes  forming  colored  reaction  with  
suitable  substrate  (light  microscopy)  or  heavy  metals(electron  microscopy) 
Methods  of  IHC: 
Direct  labeling  method: 
 Antibody  is  attached  with  a  label  by  chemical  means  and  directly  applied  
to  tissue  sections.  It  is  a  rapid  and  easy  procedure  and  carries  the  disadvantage  
of  using  multiple  antigens  which  require  separate  incubation  with  respective  
antibodies. 
Indirect  labeling  method: 
 Enzymes  are  labeled  with  secondary  antibody,  which  is  produced  against  
primary  antibody.  This  method  is  more  sensitive  and  easy  to  handle.  The  
advantages  also  include  increased  versatility,  higher  working  dilution  of  primary  
antibody,  secondary  antibodies  against  primary  antibodies  of  different  species  and  
easy  to  prepare. 
Avidin  biotin  techniques: 
 High  affinity  binding  between  biotin  and  avidin  is  used  in  this  procedure.  
Biotin  is  chemically  linked  to  primary  antibody  and  avidin  is  conjugated  
chemically  to  enzyme.  The  avidin  binds  to  biotinylated  antibody  thus  localizing  
the  peroxidase  moiety  at  the  site  of  antigen. 
 Disadvantage  of  this  technique  is  that,  the  endogenous  biotin  produces  
nonspecific  background  staining. 
Avidin  biotin  conjugate  procedure: 
 In  this  technique  primary  antibody  is  added  followed  by  biotinylated  
secondary  antibody  and  next  by  preformed  complexes  of  avidin  and  biotin  horse  
radish  peroxidase  conjugate.  This  is  a  more  sensitive  method. 
Biotin  streptavidin  system: 
 Streptavidin  is  used  in  place  of  avidin.  Streptavidin  complexes  are  more  
stable. 
Immunogold  silver  stain  technique: 
 This  is  used  in  ultrastructural  immunolocalisation.  Gold  particles  are  
enhanced  by  the  addition  of  several  layers  of  metallic  silver.  The  fine  silver  
deposits  in  the  background  &  creates  confusion  when  small  amounts  of  antigen  
are  identified. 
Polymeric  method: 
 This  technique  permits  binding  of  large  number  of  enzyme  molecules  to  
a  secondary  antibody  via  the  dextran  backbone.  Advantages  of  this  technique  are  
increased  sensitivity,  minimized  nonspecific  background  staining  and  a  reduction  
of  total  number  of  assay  steps. 
Tissue  fixation,  processing  and  antigen  retrieval  techniques: 
Tissues  for  IHC  undergo  fixation,  dehydration  and  paraffin  embedding. 
Fixation 
This  is  a  critical  step,  as  the  preservation  of  morphology  is  essential  for  
interpretation  of  IHC.10%  buffered  formalin  is  commonly  used  because  of  the  
following  advantages. 
1. Good  morphological  preservation 
2. Cheap 
3. Prevents  putrefactive  changes  in  tissues 
4. Carbohydrate  antigens  are  better  preserved. 
The  disadvantage  of  masking  of  antigens  during  fixation  can  be  overcome  
by  antigen  retrieval  techniques. 
 
 Antigen  Retrieval: 
This  procedure  involves  unmasking  of  the  antigens.  Techniques  are, 
1. Proteolytic  enzyme  digestion 
2. Microwave  antigen  retrieval 
3. Microwave  and  trypsin  and  antigen  retrieval  technique. 
4. Pressure  cooker  antigen  retrieval. 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS  AND  METHODS 
The  study  was  done  between  the  period of  November  2016-April  2017.  It  was  
carried  in  patients  with already confirmed  diagnosis  of  carcinoma  breast.  The  study  
was  approved  by  ethical  committee  of  Stanley  Medical  College. 
STUDY  POPULATION 
CASES 
The  study  sample  comprised  of  108 breast  cancer  patients.  Cases  were  chosen  
from  Department  of  General  surgery,  Stanley  Medical  College  and  Hospital.  Age  
of  the  patient  and  histological  grading  was  obtained  for  all  cases.  108  patients  
were  screened  for  receptor  status  of  estrogen  and  progesterone  as  well  as  
HER2neu  through  immunohistochemical  assay and stained with giemsa for assessing 
the stromal mast cells. 
INCLUSION  CRITERIA: 
  Patients  with  Invasive mammary  carcinoma –ductal type. 
EXCLUSION  CRITERIA: 
  All carcinomas other  than invasive mammary carcinoma- ductal type. 
Post chemotherapy and post radiotherapy cases are excluded.  
 
METHOD  OF  DATA  COLLECTION   
108 cases  were  studied  at  random  and  selected  for  doing  ER,  PR,  HER2neu  
immunohistochemistry and giemsa staining for stromal mast cells.  .The  tissues  so  
obtained  were  processed  and  sections  were  cut  at  3  microns.  Hematoxylin  and  
eosin  staining  of  the  sections  were  done  and  studied. 
METHOD  OF  TISSUE  PREPARATION  OF  IHC 
10%  buffered  formalin  was  used  for  fixing  the  specimens  .The  tissues  
were  processed  in  various  grades  of  alcohol  and  xylol  using  automated  
histokinette.  Paraffin  blocks  were  prepared  and  section  of  5  micron  thickness  
were  cut  in  semiautomatic  microtome  using  disposable  blades  and  stained  with  
hematoxylin  and  eosin.  Suitable  blocks  were  chosen  for  IHC. 
Sections  for  immunohistochemistry  were  also  cut  in  semiautomatic  
microtome  using  disposable  blades.  Slides  coated  with  chrome  alum  were  used.  
Sections  were  subjected  to  antigen  retrieval  using  pressure  cooker  technique  using  
TRIS  EDTA  (pH  9.2)  buffer  solution  and  then  treated  by  HRP  (horse  radish  
peroxidase)  polymer  technique. 
 
 
 
 
HRP  POLYMER  TECHNIQUE 
The  coated  slides  were  taken  through  the  following  stages   
1. Overnight  incubation  (first  at  70  degree  Celsius  for  one  hour,  then  at  40-
45  degree  Celsius  for  overnight) 
2. Xylene-  2  changes,  15  minutes  each 
3. Graded  alcohol-  first  with  absolute  alcohol-  2  wash,  5  minutes  each.  Then  
for  3  minutes  with  90%  alcohol  and  finally  for  3  minutes  with  70%  
alcohol 
4. Distilled  water  rinse  for  2-5  minutes 
5. Antigen  retrieval  with  pressure  cooker 
6. Wash  with  tap  water  gradually 
7. TRIS  buffer  wash  for  5  minutes,  2  changes 
8. Treatment  with  peroxidase  block  –for  inhibiting  endogenous  peroxidases  in  
the  tissue  for  10  minutes 
9. TRIS  buffer  wash  for  5  minutes,  2  changes   
10.   Application  of  primary  antibody  for  45  minutes 
11.   TRIS  buffer  wash  for  5  minutes,  2  changes 
12. Application  of  super enhancer    for  15  minutes  which  enhances  the  final  
reaction  product  by  increasing  the  sensitivity  of  antigen  antibody  reaction. 
13.   TRIS  buffer  wash  for  5  minutes,  2  changes 
14.   Application  of  SS  label  –secondary  antibody  from  the  goat  with  the  
tagged  horse  radish  peroxidase    enzyme  for  15  minutes 
15.   TRIS  buffer  wash  for  5  minutes,  2  changes 
16.   Application  of  DAB  (Diaminobenzidine)  chromogen  for  5  minutes  –this  
is  cleaved  by  the  enzyme  to  give  the  colored  product  at  the  antigen  sites 
17.   Wash  in  distilled  water  for  5  minutes 
18.   The  slides  were  counterstained  with  hematoxylin 
19.   Air  dried  and  mounted  with  DPX  (Distyrene  dibutyl  pthalide  in  Xylol) 
 
      
 
 
 
 
 
 
 
 
 
 
PROCEDURE OF GIEMSA STAIN : 
Tissue is fixed in 10 % Buffered Neutral Formalin. Sections are cut at 3 microns 
thickness. Slides are deparaffinized and hydrated in distilled water. Working 
giemsa solution is made by diluting ready-made giemsa solution with distilled 
water in 1:20 ratio. Slides are dipped in working giemsa solution for 30 mins. It 
is then differentiated in 1 % acetic acid solution for 3 seconds. Then rinsed in 
distilled water and dehydrated and mounted.  Mast cells will show violet purple 
metachromatic stain. Case is considered to be mast cell positive if one or more 
mast cells are present in ten high power field. 
 
 
 
 
 
 
 
 
  
OBSERVATION  AND  RESULTS 
 In  this  study,  we  included  108  patients  diagnosed  with  invasive mammary  
carcinoma  ductal type fulfilling  the  inclusion  and  exclusion  criteria. 
1.Age(figure 8) 
 
 
 
 
 
 
 
 
 
Table 9: Comparison of age between mast cell positive cases and negative 
cases(Independent sample t test) 
     
Groups 
Mean age 
(yrs)± SD 
Mean 
difference  
95% Confidence 
interval 
p 
value 
Mast cell 
positive cases 52.13 -0.88 -4.533, 2.77' 0.633 
          
Mast cell 
negative cases 53.01       
 
The mean age of study subjects with mast cell positive tumor is 52 years and mast cell 
negative tumor is 53 years. The mean difference of ages is -0.88. The 95% confidence 
interval contains the null value 0. Hence the difference between ages is not 
statistically significant. 
 
 
 
 
 
2.Tumor grade(chart 1) 
 
Table 10: Grading and Mast cell(Chi square) 
    
     
Tumor 
grade 
Mast cell n(%) 
Chi sq. p value 
  Positive Negative     
1 
21(19.44
) 0(0) 34.27 <0.01* 
          
2 27(25) 38(35.19)     
          
3 3(2.78) 19(17.59)      
 
 
 
The proportion of mast cell positive tumors among the tumor grades are given in table 
10. Grade 3 tumors have a higher proportion of mast cell negativitiy while Grade 1 
has higher proportion of mast cell positive tumors. This difference is statistically 
significant. 
 Out  of  21  patients  with  histological  grade one, all 21 cases were mast cell 
positive.  Out  of  65  patients  with  histological  grade  2,  27  were  mast cell  positive  
and  38  were  mast cell negative.  Out  of  22  patients  with  grade  3,  3  were  mast 
cell  positive  and  19  were  mast cell  negative.  The  correlation  was  statistically  
significant  (p  value  <0.01) 
              
 
 
 
 
 
 
 
 
 
 
Estrogen  receptor  positivity(chart 2) 
 
 
   
     
ER Mast cell n(%) Chi sq. p value 
  Positive Negative     
Positive 41(37.96) 36(33.33) 3.9066 <0.05* 
          
Negative 10(9.26) 21(19.55)     
Table 11: ER positivity and Mast cells 
 
 
 
ER positive tumors are more correlated with mast cell positivity while ER negative 
tumors are associated with mast cell negativity. The difference is statistically 
significant. 
 Out  of  108  cases  of  breast  carcinoma,  77 were  ER  positive  and  31  were  
ER  negative.  Out  of  77 ER  positive  cases,  41 were mast cells  positive   and  36  
were  mast cell negative.  Out  of  31  ER  positive  cases,  10  were mast cell  positive  
and  21  were  mast cell  negative.  The  correlation  was  statistically  significant  (p  
value<0.05) 
 
 
 
 
 
 
 
 
 
 
 
PR POSITIVITY AND MAST CELLS 
TABLE 12.   
     
PR Mast cell n(%) Chi sq. p value 
  Positive Negative     
Positive 20(18.52) 18(16.67) 0.6883 0.407 
          
Negative 31(28.70) 39(36.11)     
 
 
Chart 3-Correlation between PR and Mast cell positivity. 
There is no significant association between PR positivity and mast cell positivity, 
since the p value is more than 0.407. 
Out  of  108  cases  of  carcinoma  breast,  48  were  PR  positive  and  70  were  PR  
negative.  Out  of  48  PR  positive  cases,  30  were  mast cell positive  and  18  were  
mast cell  negative.  Out  of  70  PR  negative  cases,  31  were  mast cell  positive    and  
39  were  mast cell  negative.  The  correlation  was not  statistically  significant  (  p  
value >0.407). 
HER2neu  oncogene  positivity and mast cells chart -4 
 
 
 
HER2/neu and Mast cells table 13.   
     
HER2/neu Mast cell n(%) Chi sq. p value 
  Positive Negative     
Positive 13(12.04) 17(15.74) 0.2521 0.616 
          
Negative 38(35.19) 40(37.04)     
 
There is no significant association between HER2/neu positivity and mast cell 
positivity 
 
 
Out  of  108  cases  of  carcinoma  breast,  30  were  HER2neu  positive  and  78  
were  HER2neu  negative.  Out  of  30  HER2neu  positive  cases,  13  were  mast cell 
positive  and  17  were  mast cell  negative.  Out  of  78  HER2neu  negative  cases,  38  
were  mast cell  positive   and  40  was  mast cell  negative.  The  correlation  was not  
statistically  significant  (p  value  >0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. IMMUNOHISTOCHEMISTRY OF ER 
 
FIGURE 2. IMMUNOHISTOCHEMISTRY OF PR 
 
 
 
FIGURE 3.IMMUNOHISTOCHEMISTRY OF HER 2 NEU 
 
FIGURE 4. GIEMSA STAINING OF MAST CELLS AROUND BLOOD 
VESSELS 
 
 
 
FIGURE 7. MASTOCYTOSIS –MAST CELL CONTROL GIEMSA STAIN 
 
FIGURE 9. GRADE I BREAST CARCINOMA AND MAST CELLS 
 
 
 
FIGURE 10. GRADE 3 BREAST CARCINOMA AND MAST CELLS 
 
 
 
 
 
 
 
 
 
 
                                            DISCUSSION 
Age  distribution 
The  age  group  of  patients  included  in  our  study  varied  from  less  than  36  
to    80  years  with  most  of  the  patients  belonging  to  50-60  years  .  Mean  age  
was  52  years with mast cell positivity and 53 years with mast cell negativity.   
 Mitra Heidarpour  et  al  in  the  year  2008  conducted  a  study  which  included  
patients  with  age  less  than 30  to  more  than 85  years  (79). Mean age of the case is 
52.3 years. 
 A  study  conducted  by  Rose-Marie Amini  et  al  in  the  year  2007  included  
patients  from  27 to  95  years  with  a  mean  age  of  54  years  (80) 
 In  the  year  2004,  a  study  conducted  by Shahriar Dabiri   et  al  included  
patients  from  28  to  87  years  with  a  mean  age  of  63  years  (81) 
   Filippo Della Rovere et al conducted a study with a mean age of  67.64 years in 
2007.(82). 
Comparison  of  mast cell positivity  with  age 
In this present study the mean age of study subjects with mast cell positive tumor is 52 
years . The mean age of study subjects with mast cell negative tumor is 53 years. The 
mean difference of ages is -0.88. The 95% confidence interval contains the null value 
0. Hence the difference between ages is not statistically significant. 
 Comparison  of  mast cells  with  histological  grading 
In  the  present  study,  out  of  108  cases,  21  (19.44%)  cases  belonged  to  
grade  1,  65  (60.19%)  cases  belonged  to  grade  2  and  21  (20.37%)  cases  belonged  
to  grade  3  .  Out  of  21 grade  1  cases,  all 21  (19.44%)  were  mast cell  positive.  
The  comparison  between  grade  and  mast cell positivity  was  statistically  significant  
(<0.01)   
 In  the  year  2007,  a  study  was  conducted  by  Rose-Marie Amini  et  al.  It  
was  observed  that  mast cells    was associated with low grade and  statistically  
significant  (P  value-  0.001).  (80) 
Mitra Heidarpour   et  al  in  the  year  2008  observed  in  his  study  that  mast 
cells in stroma significantly correlated with low tumor grade. The p value is 0.004. Out  
of  54  cases  belonging  to  grade  1,  24  were  mast cell  positive    (79) 
Anna glajcar et al in 2017 conducted the study with 108 breast carcinoma cases 
and indicated tREVIEWhat high number of mast cells are seen in low grade tumors 
with the p -<0.002.(83) 
 
 
 
Comparison  of  mast cell positivity  with  ER  status 
In  the  present  study,  out  of  108  cases,  31  cases  were  ER  negative  and  
77  cases  were  ER  positive  .  Out  of  31  cases,  10  (9.26%)  were  mast cell  positive  
and  21  (19.55%)  cases  were  mast cell  negative.  Out  of  77  ER  positive  cases,  41  
(37.96%)  were  mast cell positive  and  36  (33.33%)  cases  were  mast cell  negative.  
Comparison  of  mast cell  positivity  with  ER  positivity  was  statistically  significant  
(P  value  <0.05)  . 
 Rose Marie Amini  et  al  in  the  year  2007  did  a  study  with       44    ER  
negative cases and  179  cases  were  ER  positive.  Out  of  44  ER  negative  cases,  15  
were  mast cell  positive  and  29    were  mast cell  negative.  Out  of  179  ER  positive  
cases,  105  were  mast cell   positive  and  76 were  mast cell  negative.  Comparison  
of mast cell  positivity  with  ER  was  statistically  significant  (P  value-  0.0005).   (80) 
 In  the  year  2008,  Mitra Heidarpour  observed  in  his  study,  55 cases were  
ER  negative  and  53  were  ER  positive.  Out  of  55  ER  negative  cases, 16  were  
mast cell positive  and  39  were  mast cell  negative.  Out  of  53  ER  positive  cases,  
20  were  mast cell positive  and  33  were  mast cell  negative.  Comparison  of  mast 
cell  positivity  with  ER  was  statistically  significant  (P  value-  0.04)  (79) 
 Ashish B.Rajput et  al  did  a  study  in  the  year  2007  with  4444 cases  of  
carcinoma  breast  and  observed  that  there is statistically significant correlation 
between   ER  positivity and  mast cell positivity. P value is 0.148. (84) 
Table 14-Comparision of ER and mast cell positivity in various studies 
Name  of  study ER  positive  cases Mast cell  
positivity 
P  value 
Present  study 77 41 <0.05 
Rose Marie Amini  
et  al 
179 105 <0.0005 
Mitra Heidarpour  
et  al 
53 20 0.04 
 
Comparison  of  mast cell positivity  with  PR  status 
In  the  present  study,  out  of  108  cases,  38  cases  were  PR  positive  and  70  
cases  were  PR negative .  Out  of  38  PR  positive  cases,  20  (18.52%)  were  mast 
cell  positive  and  18  (16.67%)  cases  were  mast cell negative.  Out  of  70  PR  
negative  cases,  31  (28.70%)  were  mast cell  positive  and  39  (36.11%)  cases  were 
mast cell  negative.  Comparison  of  mast cell  positivity  with  PR  positivity  was not 
statistically  significant  (P  value  >0.407) . 
Rose Marie Amini  et  al  in  the  year  2007  did  a  study  with  234 cases  of  
breast  carcinoma  out  of  which  65  cases  were  PR  negative  and  159  cases  were  
PR  positive and for 10 cases PR status was not known.  Out  of  159  PR  positive  
cases,  95  cases  were  mast cell  positive  and  64    were  mast cell negative.  Out  of  
65  PR  negative  cases,  26  were  mast cell  positive  and  39    were  mast cell  negative.  
Comparison  of  mast cell  positivity  with  PR positivity was  not  statistically  
significant  (P  value-  0.006). (80). 
 In  the  year  2008,  Mitra Heidarpour  observed  in  his  study  that  out  of  108  
patients  of  invasive  carcinoma  of  breast,  48  were  PR  positive  and  60  were  PR  
negative.  Out  of  48  PR  positive  cases,  20  were  mast cell  positive  and   28  were  
mast cell negative.  Out  of  60  PR  negative  cases,  16  were  mast cell  positive  and  
44  were  mast cell  negative.  Comparison  of  mast cell  positivity  with  PR  was  not  
statistically  significant  (P  value> 0.05) .(79) 
 
 
Table 15. comparision of PR and mast cell positivity in various studies 
  
Name  of  study PR  positive  cases Mast cell  
positivity 
P  value 
Present  study 38 20 >0.407 
Rose Marie Amini  
et al 
159 95 0.006 
Mitra Heidarpour  
et al 
48 20 >0.05 
Comparison  of  mast cell positivity  with  HER2neu  status 
In  the  present  study,  out  of  108  cases,  30  cases  were  HER2neu  positive  
and  78  cases  were  HER2neu  negative .  Out  of  30 HER2neu  positive  cases,  13  
(12.04%)  were  mast cell  positive  and  17  (15.74%)  cases  were  mast cell  negative.  
Out  of  78  HER2neu  negative  cases,  38  (35.19%)  were  mast cell  positive  and  40  
(37.04%)  case  were  mast cell  negative.  Comparison  of  mast cell  positivity  with  
HER2neu  positivity  was not statistically  significant  (P  value  0.616) . 
In  the  year  2008,  Mitra Heidarpour  observed  in  his  study  that  out  of  108  
patients  of  invasive  carcinoma  of  79  cases  were  HER2neu  positive  and  29  cases  
were  HER2neu  negative.  Out  of  79  HER2neu  positive  cases,  24  (66.7%)  were  
mast cell  positive  and  55  (76.4%)  were  mast cell  negative.  Out  of  29  HER2neu  
negative  cases,  12(33.3%)  were  mast cell positive  and  17  (23.6%)  were  mast cell  
negative.  Comparison  of  mast cell  positivity  with  HER2neu  was not statistically  
significant  (P  value-  >0.05).  
Jianfeng Sang et al in 2016 did a study in 219 cases of breast cancer and found 
that no significant association between the mast cell positivity and her 2 neu status.(85)  
 Anna Glajcar et al 2017 found that mast cell positivity was seen in breast without 
HER2 overexpression when compared to tumors with HER2 overexpression.(83). 
 
 
CONCLUSION 
This    study    was    carried    out    in    the    Department    of    Pathology,    
Govt.    Stanley    Medical    College,    in    collaboration    with    the    Department    
of    General  surgery,    Govt.  Stanley  Hospital.    Total  of  108  modified  radical  
mastectomy  specimens  were  taken  for  this  study 
 The  stromal  mast cells  had  significant  correlation  with  low  
histological  grade  (Grade  1). 
  The  stromal  mast cells  had  significant  correlation  with  ER  
positivity.  
 There  is  no  correlation  between  mast cell positivity  and  age  of  the  
patient 
 There  is  no  correlation  between  mast cell positivity  and  PR positivity. 
 There  is  no  correlation  between  mast cell positivity  and  Her2 
positivity. 
Recently Mast cells have gained the attention as a potential target in breast 
carcinoma . Drugs like cromolyn and Tranilast can be employed in chemotherapy 
as these drugs inhibit mast cell degranulation and prevent tumor growth and 
angiogenesis.  
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